Compositions and methods for the treatment of nasal conditions
The invention provides compositions and methods for treating nasal congestion. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists. The compositions preferably include brimonidine.
1. A composition comprising:
brimonidine, or a pharmaceutically acceptable salt thereof;
a preservative consisting of a mixture of disodium ethylenediaminetetraacetic acid at an amount of from about 0.01% to about 0.1% w/v and benzyl alcohol at an amount of from about 0.1% to about 1.0% w/v;
a vehicle consisting of a mixture of a coprecipitate containing carboxymethyl cellulose and microcrystalline cellulose at an amount of from about 1.0% to about 5.0% w/v, wherein the ratio of carboxymethyl cellulose to microcrystalline cellulose is from about 9:91 to about 13:87, polyvinylpyrrolidone at an amount of from about 1.0% to about 5.0% w/v and hydroxypropyl cellulose at an amount of from about 0% to about 5% w/v;
a tonicity adjustor consisting of glycerin at an amount of from about 0.1% to about 1.0% w/v;
a pH adjustor consisting of a mixture of sodium phosphate, dibasic at an amount of from about 0.01% to about 0.1% w/v and sodium phosphate, monobasic at an amount of from about 0.1% to about 1.0% w/v; and
a permeation enhancer consisting of a mixture of a polyethylene glycol at an amount of from about 1.0% to about 10.0% w/v and menthol at an amount of from about 0.001% to about 0.1% w/v;
wherein the brimonidine is at an amount of from about 0.03% to about 0.035% w/v, wherein pH of the composition is between about 5.0 and about 8.0, and wherein w/v denotes weight by volume.
2. A method of treating a nasal condition in a subject in need thereof comprising administering to the subject a pharmaceutically effective amount of the composition of claim 1 .
3. The composition of claim 1 wherein:
the brimonidine is at an amount of about 0.035% w/v;
the coprecipitate is Avicel 591® at an amount of about 3.0% w/v;
the polyvinylpyrrolidone is at an amount of about 3.0% w/v;
the polyethylene glycol is polyethylene glycol-32 at an amount of about 5.0% w/v;
the sodium phosphate, dibasic is at an amount of about 0.0975% w/v;
the sodium phosphate, monobasic is at an amount of about 0.5525% w/v;
the disodium ethylenediaminetetraacetic acid is at an amount of about 0.03% w/v;
the benzyl alcohol is at an amount of about 0.25% w/v;
the glycerin is at an amount of about 0.5% w/v;
the menthol is at an amount of about 0.00375% w/v;
the hydroxypropyl cellulose is at an amount of about 0.0% w/v.
4. The composition of claim 1 wherein:
the brimonidine is at an amount of about 0.035% w/v;
the coprecipitate is Avicel 591® at an amount of about 3.0% w/v;
the polyvinylpyrrolidone is at an amount of about 3.0% w/v;
the polyethylene glycol is polyethylene glycol-32 at an amount of about 5.0% w/v;
the sodium phosphate, dibasic is at an amount of about 0.0975% w/v;
the sodium phosphate, monobasic is at an amount of about 0.5525% w/v;
the disodium ethylenediaminetetraacetic acid is at an amount of about 0.03% w/v;
the benzyl alcohol is at an amount of about 0.25% w/v;
the glycerin is at an amount of about 0.5% w/v;
the menthol is at an amount of about 0.00375% w/v;
the hydroxypropyl cellulose is at an amount of about 1.0% w/v.
5. The composition of claim 1 wherein:
the brimonidine is at an amount of about 0.035% w/v;
the coprecipitate is Avicel 591® at an amount of about 3.0% w/v;
the polyvinylpyrrolidone is at an amount of about 3.0% w/v;
the polyethylene glycol is polyethylene glycol-32 at an amount of about 5.0% w/v;
the sodium phosphate, dibasic is at an amount of about 0.0975% w/v;
the sodium phosphate, monobasic is at an amount of about 0.5525% w/v;
the disodium ethylenediaminetetraacetic acid is at an amount of about 0.03% w/v;
the benzyl alcohol is at an amount of about 0.25% w/v;
the glycerin is at an amount of about 0.5% w/v;
the menthol is at an amount of about 0.015% w/v;
the hydroxypropyl cellulose is at an amount of about 2.0% w/v.
6. A composition comprising:
brimonidine or a pharmaceutically acceptable salt thereof at an amount of about 0.035% w/v;
Avicel 591® at an amount of about 3.0% w/v;
polyvinylpyrrolidone at an amount of about 3.0% w/v;
polyethylene glycol-32 at an amount of about 5.0% w/v;
sodium phosphate, dibasic at an amount of about 0.0975% w/v;
sodium phosphate, monobasic at an amount of about 0.5525% w/v;
disodium EDTA at an amount of about 0.03% w/v;
benzyl alcohol at an amount of about 0.25% w/v;
glycerin at an amount of about 0.5% w/v;
menthol at an amount of about 0.00375% w/v; and
hydroxypropyl cellulose at an amount of about 2.0% w/v, wherein w/v denotes weight by volume.
7. A method of treating a nasal condition in a subject in need thereof comprising administering to said subject a pharmaceutically effective amount of the composition of claim 6 .
8. The method of claim 7 wherein the nasal condition is selected from the group consisting of insufficient nares patency for peak athletic performance, rhinitis medicamentosa secondary to oxymetazoline nasal spray, allergic rhinitis, vasomotor rhinitis, sleep apnea, nasal secretion induced gastroesophogeal reflux, sleep apnea due to obstructed or partially obstructed turbinates, and treatment of partial or complete nasal obstruction due to nasal polyps or a combination thereof.